You can’t get far with $150,000 in drug development, a painful realization that 9 Meters Biopharma knows all too well, as the North Carolina-based biotech filed for bankruptcy. The company disclosed ...
RALEIGH, NC / ACCESSWIRE / January 31, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, ...
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today ...
9 Meters Biopharma’s celiac disease drug isn’t measuring up in a phase 3 trial. After an interim analysis found that the study needs an enrollment count that is too large to support continuation, the ...
RALEIGH — Introducing 9 Meters Biopharma, the new company birthed from the merger of Raleigh-based Innovate Biopharmaceuticals, a clinical stage biotechnology company focused on developing novel ...
9 Meters Biopharma Inc NMTR shares plummeted after the company filed for Chapter 11 bankruptcy protection, according to a regulatory filing on Tuesday. The company said that after considering all ...
In this case, more is just too much. The number of participants needed to determine a significant clinical outcome in 9 Meters Biopharma Inc.’s phase III of larazotide in treating celiac disease has ...
RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an ...
RALEIGH, NC / ACCESSWIRE / December 9, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results